Show simple item record

dc.contributor.authorEadie, Ashley
dc.date.accessioned2016-09-06T12:08:41Z
dc.date.available2016-09-06T12:08:41Z
dc.date.issued2016-09-06T12:08:41Z
dc.identifier.urihttp://hdl.handle.net/10222/72201
dc.description.abstractThe heme metabolism pathway remains a novel therapeutic target for heart failure treatment. However, how heme is regulated in the failing heart remains to be understood. To investigate the molecular mechanisms underlying heme regulation and its potential modulation by hypoxia inducible transcription factors, we investigated the expression of heme regulatory enzymes and hypoxia inducible factors in clinical heart failure and experimental heart failure rodent models. Here we show that heme regulatory enzymes - delta-aminolevulinic acid synthases (ALAS) and heme oxygenases (HMOX) - and heme bioavailability changed significantly in clinical and experimental rodent models of heart failure over time, that (HMOX1) protein levels remained relatively unchanged or decreased in experimental heart failure, and that HMOX1 expression is induced synergistically in heme-replete hypoxia, likely by hypoxia inducible factor 2a (HIF2a).en_US
dc.language.isoenen_US
dc.subjectHeart failureen_US
dc.subjectHeme metabolismen_US
dc.subjectHypoxiaen_US
dc.titleTHE ROLE OF HEME REGULATORY ENZYMES IN MYOCYTES UNDER STRESSen_US
dc.typeThesisen_US
dc.date.defence2016-08-25
dc.contributor.departmentDepartment of Pharmacologyen_US
dc.contributor.degreeMaster of Scienceen_US
dc.contributor.external-examinerDr. T Alexander Quinnen_US
dc.contributor.graduate-coordinatorDr. Kishore Pasumarthien_US
dc.contributor.thesis-readerDr. George Robertsonen_US
dc.contributor.thesis-supervisorDr. Keith R. Brunten_US
dc.contributor.ethics-approvalReceiveden_US
dc.contributor.manuscriptsNot Applicableen_US
dc.contributor.copyright-releaseNot Applicableen_US
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record